Page 276 - Haematologica Vol. 107 - September 2022

LETTER TO THE EDITOR
1Molecular Medicine and Gene Therapy, Lund Stem Cell Center and 2Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Correspondence:
A. SUBRAMANIAM - agatheeswaran.subramaniam@med.lu.se J. LARSSON - jonas.larsson@med.lu.se.
doi:10.3324/haematol.2021.280303
Received: November 18, 2021. Accepted: May 27, 2022. Prepublished: May 31, 2022.
©2022 Ferrata Storti Foundation Published under a CC-BY-NC license
Disclosures
No conflicts of interest to disclose.
Contributions
AS, CS, KZ, LS, AuB, AB, EA, SH, and NM performed the experiments and acquired data. LMC and KP helped with the cohesion assay. CS,
References
1. Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014;99(8):1277-1284.
2. Kasi PM, Litzow MR, Patnaik MM, Hashmi SK, Gangat N. Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets. Leuk Res Rep. 2016;5:7-10.
3. Losada A. Cohesin in cancer: chromosome segregation and beyond. Nat Rev Cancer. 2014;14(6):389-393.
4. Kon A, Shih LY, Minamino M, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet. 2013;45(10):1232-1237.
5. Yoshida K, Toki T, Okuno Y, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013;45(11):1293-1299.
6. Solomon DA, Kim T, Diaz-Martinez LA, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science. 2011;333(6045):1039-1043.
7. Mazumbar C, Shen Y, Xavy S, et al. Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation. Cell Stem Cell. 2015;17(6):675-688.
8. Thota S, Viny AD, Makishima H, et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood.
TF and MM performed molecular analysis of the AML samples and provided the materials. AS and JL conceived and designed the study, interpreted the results and wrote the manuscript.
Acknowledgements
We would like to thank the staff at animal house and FACS core facilities for their excellent support. We also would like to thank Jenny G. Johansson for helping with the AAV vector production.
Funding
This work was funded to JL by grants from the Swedish Research Council, the Swedish Cancer Foundation, the Swedish Pediatric Cancer Foundation, Knut och Alice Wallenbergs Stiftelse and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No. 648894). AS was supported from the Swedish Cancer Foundation, Royal Physiographic Society of Lund and Lady TATA memorial trust. The work was further supported by the HematoLinné and StemTherapy programs at Lund University.
Data-sharing statement
The datasets generated or analyzed in this study are available upon reasonable request to the corresponding authors (AS and JL).
2014;124(11):1790-1798.
9. Galeev R, Baudet A, Kumar P, et al. Genome-wide RNAi screen
identifies cohesin genes as modifiers of renewal and
differentiation in human HSCs. Cell Rep. 2016;14(12):2988-3000. 10. Kong X, Ball AR, Jr., Pham HX, et al. Distinct functions of human
cohesin-SA1 and cohesin-SA2 in double-strand break repair. Mol
Cell Biol. 2014;34(4):685-698.
11. Benedetti L, Cereda M, Monteverde L, Desai N, Ciccarelli FD.
Synthetic lethal interaction between the tumour suppressor STAG2 and its paralog STAG1. Oncotarget. 2017;8(23):37619-37632.
12. van der Lelij P, Lieb S, Jude J, et al. Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts. Elife. 2017;6:e26980.
13. Viny AD, Bowman RL, Liu Y, et al. Cohesin members Stag1 and Stag2 display distinct roles in chromatin accessibility and topological control of HSC self-renewal and differentiation. Cell Stem Cell. 2019;25(5):682-696.
14. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A. 2014;111(7):2548-2553.
15. van der Lelij P, Newman JA, Lieb S, et al. STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers. Life Sci Alliance. 2020;3(7):e202000725.
Haematologica | 107 September 2022
2275